share_log

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-10% Owner CR Group L.P.

T2 Biosystems | 4：持股變動聲明-股東 CR Group L.P.
美股sec公告 ·  04/17 08:41
牛牛AI助理已提取核心訊息
CR Group L.P., a significant stakeholder in T2 Biosystems, Inc. [TTOO], reported a series of acquisitions of common stock on April 12, 2024. The transactions were made through various entities associated with CR Group L.P. and were all indirect acquisitions. A total of 682,036 shares were acquired by CRG Partners III L.P., 424,716 shares by CRG Partners III - Parallel Fund (A) L.P., 136,409 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,647,315 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 390,142 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions significantly increased CR Group L.P.'s holdings in T2 Biosystems, with the total number of shares held after the transactions amounting to 4,104,838. The nature of the shares is indirect, and the transactions are classified as grants, awards, or other acquisitions.
CR Group L.P., a significant stakeholder in T2 Biosystems, Inc. [TTOO], reported a series of acquisitions of common stock on April 12, 2024. The transactions were made through various entities associated with CR Group L.P. and were all indirect acquisitions. A total of 682,036 shares were acquired by CRG Partners III L.P., 424,716 shares by CRG Partners III - Parallel Fund (A) L.P., 136,409 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,647,315 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 390,142 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions significantly increased CR Group L.P.'s holdings in T2 Biosystems, with the total number of shares held after the transactions amounting to 4,104,838. The nature of the shares is indirect, and the transactions are classified as grants, awards, or other acquisitions.
T2 Biosystems, Inc. [TTOO] 的重要利益相關者CR集團有限責任公司於2024年4月12日報告了一系列普通股收購。這些交易是通過與CR Group L.P. 相關的多個實體進行的，均爲間接收購。CRG Partners III L.P. 共收購了682,036股股票，CRG Partners III——平行基金（A）有限責任公司共收購了424,716股股票，CRG Partners III L.P. 收購了136,409股股票，CRG Partners III L.P. 收購了1,647,315股股票，CRG Partners III L.P. 收購了1,647,315股...展開全部
T2 Biosystems, Inc. [TTOO] 的重要利益相關者CR集團有限責任公司於2024年4月12日報告了一系列普通股收購。這些交易是通過與CR Group L.P. 相關的多個實體進行的，均爲間接收購。CRG Partners III L.P. 共收購了682,036股股票，CRG Partners III——平行基金（A）有限責任公司共收購了424,716股股票，CRG Partners III L.P. 收購了136,409股股票，CRG Partners III L.P. 收購了1,647,315股股票，CRG Partners III L.P. 收購了1,647,315股股票，CRG Partners III L.P. 收購了390,142股股票-Parallel Fund B（開曼）L.P. 這些收購極大地增加了CR Group L.P.持有T2 Biosystems的股份，交易後持有的股份總數爲4,104,838股。股份的性質是間接的，交易被歸類爲贈款、獎勵或其他收購。

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。